Premium
Cutting‐edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies
Author(s) -
Beck A.,
Debaene F.,
Diemer H.,
WagnerRousset E.,
Colas O.,
Van Dorsselaer A.,
Cianférani S.
Publication year - 2015
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/jms.3479
Subject(s) - biosimilar , chemistry , antibody , characterization (materials science) , computational biology , tandem mass spectrometry , mass spectrometry , microbiology and biotechnology , nanotechnology , chromatography , immunology , medicine , biology , materials science
Antibodies represent a family of clinically relevant compounds with growing commercial potential. From a market perspective, their large size and structural complexity offers a natural protection against molecular duplication. However, copies of previously approved antibodies can be produced from different cell clones as biosimilars. Regulatory approval of biosimilar antibodies are based on comprehensive analytical characterization of the molecular differences between the biosimilar and original antibody. The approval process can be abbreviated if the biosimilar possess a high degree of molecular similarity to the original approved antibody, providing a strong commercial incentive for accurate characterization of biosimilar and approved antibodies. In this Special Feature, Alain Beck of Pierre Fabre Center of Immunology, and Sarah Cianferani of the University of Strasbourg present a tutorial of mass spectrometry as a powerful tool for antibody characterization.